Research Briefs: Edwards Starts New Sapien 3 Trial; Upper Airway Stimulator For Sleep Apnea
This article was originally published in The Gray Sheet
Executive Summary
FDA has approved an investigational device exemption for Edwards Lifesciences’ trial of the Sapien 3 transcatheter aortic valve in intermediate-risk patients. The New England Journal of Medicine publishes results of the STAR trial of Inspire Medical’s upper airway stimulator for treatment of sleep apnea.
You may also be interested in...
Edwards’ Third-Generation Sapien TAVI System Launched In Europe
Edwards Lifesciences is launching its Sapien 3 transcatheter aortic valve system in Europe following receipt of a CE mark.
Regulatory Briefs: HHS Agenda; Cardiopulmonary Blood Pump Reclassification; FDA Meetings
HHS issued a semiannual report detailing the regulatory agenda for FDA in 2014. FDA reclassifies cardiopulmonary bypass blood pumps. More regulatory news.
Early Registry Outcomes Suggest TAVR Roll-Out Has Been Successful So Far
The first report from the U.S. TVT Registry of transcatheter aortic valve replacement shows procedural and in-hospital outcomes comparable to those seen in randomized trials and international registries.